Track Gland Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 6.10 %
Low
2,299.2
High
2,529.3
1 Month returns: 10.02 %
Low
2,166.8
High
2,529.3
1 Year returns: 31.14 %
Low
1,573.6
High
2,529.3
3 Year CAGR: 31.90 %
Low
1,042.0
High
2,529.3
5 Year CAGR: -6.82 %
Low
861.0
High
4,350.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Gland Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Gland Pharma Ltd. Shareholding Pattern
Quarterly breakdown of Gland Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Gland Pharma Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Gland Pharma Ltd.?
The current share price of Gland Pharma Ltd. is ₹ 2,455.90 as of 3 Jul 2026.
What is the market capitalisation of Gland Pharma Ltd.?
The market capitalisation of Gland Pharma Ltd. stands at ₹ 40,352.50 Cr.
What is the PE ratio of Gland Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Gland Pharma Ltd. is 39.28 as of the latest trailing twelve months data.
What is the ROE and ROCE of Gland Pharma Ltd.?
Gland Pharma Ltd. has a Return on Equity (ROE) of 10.53% and a Return on Capital Employed (ROCE) of 12.00% as per the latest financial reports.
What is the 52-week high and low of Gland Pharma Ltd.?
The 52-week high of Gland Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Gland Pharma Ltd.?
The dividend yield of Gland Pharma Ltd. is 0.74% based on the current market price.
What is the FII and DII holding in Gland Pharma Ltd.?
Foreign Institutional Investors (FII) hold 7.29%, Domestic Institutional Investors (DII) hold 33.13% and retail/public investors hold 2.85% of Gland Pharma Ltd. shares.
What sector does Gland Pharma Ltd. belong to?
Gland Pharma Ltd. operates in the Healthcare sector. 66.67% of analysts have a Buy or Strong Buy rating on Gland Pharma Ltd. with a consensus target price of ₹ 2,260.00, implying 7.61% downside from current levels.
What is the beta of Gland Pharma Ltd.?
The beta of Gland Pharma Ltd. is 0.56, indicating its price volatility relative to the broader market. Over the past 1 year, Gland Pharma Ltd. has delivered an absolute return of 38.60%.
What is the RSI of Gland Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Gland Pharma Ltd. is 67.48, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Company Profile
Overview of Gland Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a r...
SY.NO.143-148,150 &151, NEAR GANDI MAISAMMA X ROADS, D.P.PALLY,DUNDIGAL, DUNDIGAL, GANDIMAISAMMA(M) MEDCHAL MALKAJGIRI RANGAREDDI, , 500043, India
Corporate Actions
History of Gland Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 20/share
Record date: 11th Aug 2026Ex-date: 11th Aug 2026
Announced on: 15th May 2026
Dividend₹ 18/share
Record date: 14th Aug 2025Ex-date: 14th Aug 2025
Announced on: 20th May 2025
Dividend₹ 20/share
Record date: 16th Aug 2024Ex-date: 16th Aug 2024
Announced on: 22nd May 2024
Sep 2016
Sep 2017
Sep 2018
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Promoter
41.61
41.92
96.08
58.36
58.25
58.14
58.02
58.00
58.00
57.87
57.86
57.86
57.86
57.86
57.86
57.86
57.86
51.83
51.83
51.83
51.83
51.83
51.83
51.83
51.83
Indian Promoter
37.30
41.92
22.08
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Foreign Promoter
4.31
0.00
74.00
58.36
58.25
58.14
58.02
58.00
58.00
57.87
57.86
57.86
57.86
57.86
57.86
57.86
57.86
51.83
51.83
51.83
51.83
51.83
51.83
51.83
51.83
Institutions
0.00
0.00
0.00
23.54
23.12
22.54
22.76
22.96
23.18
26.77
28.01
27.79
27.56
26.18
27.36
28.21
28.82
39.71
39.84
39.84
40.17
40.25
40.55
40.56
40.65
Mutual Funds / UTI
0.00
0.00
0.00
9.73
10.20
11.09
10.98
10.55
11.22
15.54
18.48
19.49
20.25
20.48
19.79
21.34
23.01
30.53
32.83
32.37
31.16
30.67
30.19
31.42
31.78
FI/Bank/Insurance
0.00
0.00
0.00
0.45
0.48
0.48
0.41
0.66
0.72
1.17
2.10
2.59
2.02
1.80
1.80
1.80
1.21
1.29
1.50
1.38
1.32
1.27
1.30
1.36
1.35
Govt
0.00
0.00
0.00
-
-
-
-
-
0.00
0.00
0.00
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.00
0.00
0.00
12.73
11.87
10.44
11.01
11.30
10.72
9.41
6.09
4.67
4.33
2.80
4.91
4.05
3.59
6.88
4.48
5.04
6.90
7.39
7.90
7.58
7.29
Other Institutions
0.00
0.00
0.00
0.63
0.56
0.54
0.36
0.45
0.52
0.65
1.34
1.05
0.96
1.10
0.86
1.03
1.01
1.01
1.04
1.05
0.79
0.92
1.14
0.21
0.23
Non-Institution
58.39
58.08
3.92
18.10
18.63
19.32
19.21
19.05
18.82
15.35
14.13
14.34
14.58
15.96
14.78
13.93
13.32
8.45
8.32
8.33
7.99
7.93
7.63
7.61
7.52
Bodies Corporate
48.35
48.00
3.87
14.78
14.84
14.79
14.77
14.74
14.44
10.58
9.93
9.79
9.84
9.85
9.81
9.71
9.67
4.71
4.70
4.71
4.70
4.71
4.71
4.70
4.67
Others (incl. Retail)
No. of shareholders
10.04
6
10.08
0
0.05
0
3.32
76,529
3.79
83,574
4.53
97,191
4.44
1,08,196
4.31
1,07,919
4.38
1,08,064
4.77
1,15,898
4.20
1,26,805
4.55
1,47,622
4.74
1,49,785
6.11
1,81,140
4.97
1,61,010
4.22
1,35,459
3.65
1,21,894
3.74
1,22,095
3.62
1,21,774
3.62
1,20,403
3.29
1,13,253
3.22
1,10,118
2.92
96,567
2.91
94,023
2.85
90,972
2,455.909.7 (0.40%) D
31.56% in past 1 year
Stock Analysis
Fundamental analysis overview of Gland Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 94.9 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
94.9 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 3.08% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
Moderate ROE but improving trend
The company reported moderate ROE of 10.53% for 12-month ended 31 Mar 2026 but ROE improved by 271 bps from 1 year ago
What is ROE (FY)?
High and improving operating margin
The company reported strong operating margin of 18.75% for 12-month ended 31 Mar 2026 and operating margin improved by 289 bps from 1 year ago
What is Operating profit margin?
Moderate revenue growth and above median growth of industry
The company delivered moderate revenue growth of 14.5% for 12-month ended 31 Mar 2026 and the growth was 3.26 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 14.5
-82.35114662
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 46.89% for 12-month ended 31 Mar 2026 and the growth was 38.77 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.03 as on 31 Mar 2026 and Debt to Equity remained same in the last 1 year
What is Debt to Equity?
Company's earnings are of high quality
Earnings quality score of 74.6 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
74.6 / 100
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 39.28 indicates that the stock is expensive on a standalone basis and is at a 29.81% premium to industry median P/E
What is P/E Ratio?
Median: 30.26
Value 39.28
-215.443183
Low dividend yield
The company has a low dividend yield of 0.74%
What is Dividend yield?
Neutral
Not enough talking points with neutral stance
No red flags found!
No significant red flags found in the stock.
Holdings and Presence
Indices and prominent investors with a stake in this stock.